Implementing personalized medicine in a cancer center

Cancer Journal

Volumn 17, Issue 6, 2011, Pages 528-536

  Fenstermacher, David A ^a,b   Wenham, Robert M ^a   Rollison, Dana E ^a   Dalton, William S ^b  

^a Department of Biomedical Informatics ^*  (United States)

^b H LEE MOFFITT CANCER CENTER AND RESEARCH INSTITUTE   (United States)

Author keywords

biological markers; biological specimen banks; database; dictionary; factual; genomics; Individualized medicine; informed consent; neoplasms; personalized medicine; tissues

Indexed keywords

CANCER CENTER; CANCER PATIENT; CLINICAL PROTOCOL; HOSPITAL; HUMAN; INFORMATION TECHNOLOGY; INFORMED CONSENT; PATIENT RIGHT; PERSONALIZED MEDICINE; PRIORITY JOURNAL; REVIEW; UNITED STATES;

CANCER CARE FACILITIES; HUMANS; INDIVIDUALIZED MEDICINE; NEOPLASMS; PROSPECTIVE STUDIES; UNITED STATES;

EID: 83755174099     PISSN: 15289117     EISSN: 1540336X     Source Type: Journal    
DOI: 10.1097/PPO.0b013e318238216e     Document Type: Review

References (20)

1. Siegel R, Ward E, Brawley O, et al. Cancer statistics, the impact of eliminating socioeconomic and racial disparities on premature cancer deaths. CA Cancer J Clin. 2011;61:212-236.
2. Society AC. Cancer Facts & Figures 2009. Atlanta, GA; 2009 [updated 2009; cited 2011 June 23]. Available at: www.cancer.org/Cancer/ CancerBasics/economic-impact-of-cancer.
3. Senate Confirmation Hearings: Senate Confirmation Hearings, US Senate (April 2, 2009).
4. Druker BJ, Guilhot F, O'Brien SG, et al. Five-year follow-up of patients receiving imatinib for chronicmyeloid leukemia. N Engl J Med. 2006;355: 2408-2417. (Pubitemid 44903745)
5. Ganjoo KN, Wakelee H. Review of erlotinib in the treatment of advanced nonYsmall cell lung cancer. Biologics. 2007;1:335-346.
6. Paez JG, Janne PA, Lee JC, et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science. 2004;304: 1497-1500. (Pubitemid 38720929)
7. Chapman PB, Hauschild A, Robert C, et al. Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med. 2011;364:2507-2516.
8. Yeatman TJ, Mule J, Dalton WS, et al. On the eve of personalized medicine in oncology. Cancer Res. 2008;68:7250-7252.
9. Koomen JM, Haura EB, Bepler G, et al. Proteomic contributions to personalized cancer care. Mol Cell Proteomics. 2008;7:1780-1794.
10. U.S. DoHaHS. Personalized Health care initiative. Personalized health care: pioneers, partnerships, progress. 2008 [updated 2008]. Available at: www.hhs.goc/myhealthcare/news/phc-2008-report.pdf.
11. Maydanchik A. Data Quality Assessment. Bradley Beach, NJ: Technics Publications; 2007.
12. Covitz PA, Hartel F, Schaefer C, et al. caCORE: a common infrastructure for cancer informatics. Bioinformatics. 2003;19:2404-2412. (Pubitemid 38016640)
13. ISO/IEC. Information TechnologyVMetadata Registries (MDR). International Organization for Standardization/International Electrotechnical Commission. 2004 [updated 2004; cited 2011 June 15]. Available at: www.iso.org/iso/search.htm? qt=11179&searchSubmit=Search&sort= rel&type=simple&published=on.
14. Codd E, ed. Further Normalization of the Database Relational Model. Courant Computer Science Symposia Series 6, WData Base Systems. New York, NY: Prentice-Hall; 1972.
15. Dalton WS, Sullivan DM, Yeatman TJ, et al. The 2010 Health Care Reform Act: a potential opportunity to advance cancer research by taking cancer personally. Clin Cancer Res. 2010;16:5987-5996.
16. Abernethy AP, Etheredge LM, Ganz PA, et al. Rapid-learning system for cancer care. J Clin Oncol. 2010;28:4268-4274.
17. Dasgupta P, Rizwani W, Pillai S, et al. ARRB1-mediated regulation of E2F target genes in nicotine-induced growth of lung tumors. J Natl Cancer Inst. 2011;103:317-333.
18. Pillai S, RizwaniW, Li X, et al. ID1 facilitates the growth and metastasis of nonYsmall cell lung cancer in response to nicotinic acetylcholine receptor and epidermal growth factor receptor signaling. Mol Cell Biol. 2011;31:3052-3067.
19. Eschrich S, Zhang H, Zhao H, et al. Systems biology modeling of the radiation sensitivity network: a biomarker discovery platform. Int J Radiat Oncol Biol Phys. 2009;75:497-505.
20. Cogle CR, Craig BM, Rollison DE, et al. Incidence of the myelodysplastic syndromes using a novel claims-based algorithm: high number of uncaptured cases by cancer registries. Blood. 2011;117: 7121-7125.